Target intelligence / Profile preview

O-antigen of Shigella sonnei lipopolysaccharide

Molecular classification
Other (Bacterial surface polysaccharide, component of lipopolysaccharide), Antigen
01

Overview

The O-antigen of Shigella sonnei lipopolysaccharide is an immunodominant, high-molecular-weight polysaccharide that constitutes the distal, repeating glycan portion of the lipopolysaccharide (LPS) molecules on the outer membrane of Shigella sonnei. The O-antigen is highly species- and strain-specific, composed of unique repeating oligosaccharide units containing two rare sugars—2-acetamido-2-deoxy-L-altruronic acid (L-AltNAcA) and 2-acetamido-2-deoxy-L-fucose (FucNAc4N)—which are not found in other Shigella serogroups. This antigenic structure plays a central role in pathogenicity, immune recognition, and evasion, and is the molecular target for protective antibodies during infection and for vaccines. In S. sonnei, the O-antigen is encoded by genes on a virulence plasmid and is essential both for full virulence and for inducing a protective immune response. Conjugate vaccines and monoclonal antibodies targeting the O-antigen are under active development and have shown potential for disease prevention[1][2][3][4][5][6][7].

Other names
Shigella sonnei O-antigenS. sonnei OAgO-specific polysaccharide of Shigella sonneiShigella sonnei O-polysaccharide
02

Mechanism of action

Induction of immune response: vaccine polysaccharide-protein conjugates (e.g., O-antigen conjugated to carrier proteins) elicit protective anti-O-antigen antibodies that mediate bacterial clearance[4][7]. Direct neutralization or bactericidal activity by monoclonal antibodies, leading to opsonization and complement-mediated killing[7].

03

Biological functions

Immune evasionElicitation of host immune responseModulation of pathogenesisProtective antigen for vaccine development
04

Disease associations

Infection (key virulence factor and immunogen in Shigella sonnei infection)Other (important as a target for vaccine design and immune detection)
05

Safety considerations

Polysaccharide nature leads to T-cell–independent immune responses in unconjugated form, which can be suboptimal or poorly effective in infants and young children, necessitating conjugate vaccines[4].Potential for antigenic mismatch or variation affecting effectiveness of vaccine or antibody therapies[2][3][5].
06

Interacting drugs

S. sonnei O-antigen–protein conjugate vaccines[4]

1 more in the full profile.

07

Biomarkers

Anti–S. sonnei O-antigen antibodies in vaccinated or infected individuals (useful for diagnosis, epidemiology, and monitoring vaccine efficacy)[4][6]

Beyond the preview

Go deeper on O-antigen of Shigella sonnei lipopolysaccharide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on O-antigen of Shigella sonnei lipopolysaccharide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call